Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes

NCT03740919 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03740919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03740919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
April 7, 2019
Completion date
July 2, 2021
Enrollment
751 (actual)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus